Category: Caribou Biosciences

  • AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies

    Shots: Caribou to receive $40M up front in cash & equity investment, ~$300M in development, regulatory, and launch milestones along with additional commercial milestones and global royalties AbbVie will utilize and gets exclusive rights to Caribou’s next-generation Cas12a chRDNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies directed to specified […]